Close this search box.
Subscriber Log In

PD(L)anner – February 2023

The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.

You can also listen to our podcast that accompanies this edition in which Jacob Plieth talks through some of the highlights with Bertrand Delsuc, publisher of BioTech Radar.


Download Now


Related Blogs

Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.